ReviewBiomolecules2022
Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.
Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 486 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
486 citing papers in PubMed, 4 syntheses or guidelines pooled it, 750 citations in OpenAlex.
- Association between diabetic kidney disease and visceral adiposity index: a meta-analysis.BMC nephrology · 2026Pooled it
- Prediabetes and cataract risk in adults: A systematic review and meta-analysis.Biomolecules & biomedicine · 2026Pooled it
- Research progress on risk prediction models for the diabetic foot.Acta diabetologica · 2025Pooled it
- Creatinine as a predictor of proliferative diabetic retinopathy among patients with type 2 diabetes mellitus: a systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- Glycemic Status and Effect of Immediate Intensive Statin on Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Trial.CNS neuroscience & therapeutics · 2026 · on this mapTrial
- Serum advanced glycation end-products as a biomarker of cumulative glycaemic burden and complications in type 2 diabetes: a pilot study.Annals of medicine · 2026Article
- Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Article
- Disorganized bone collagen fibers in early-stage type 2 diabetes mellitus and its association with adipose tissue redistribution.European radiology experimental · 2026Article
- Shared mechanisms of musculoskeletal dysfunction in type 2 diabetes mellitus: Insights into future therapeutic directions (Review).International journal of molecular medicine · 2026Review
- Castanopsis echinocarpa extract attenuates diabetes-associated peripheral-to-central auditory electrophysiological dysfunction in streptozotocin-induced diabetic mice.Metabolic brain disease · 2026Article
- Antioxidants as a Link Between Diabetes and Potential Plant-Based Therapies.Antioxidants (Basel, Switzerland) · 2026Review
- Levocarnitine attenuates diabetic seminal vesicle fibrosis in association with improved lipid metabolism and reduced ER stress.iScience · 2026Article
- In Vitro Digestive-Enzyme Inhibition and Antiglycation Activity ofCurrent issues in molecular biology · 2026Article
- A2BAR Antagonism Mitigates Pulmonary Inflammation and Fibrosis and Restores Macrophage M1/M2 Balance in Diabetic Rats.International journal of molecular sciences · 2026Article
- Review
- Gegen Flavonoids and Huangqi Saponins Combination Ameliorates Diabetic Nephropathy By Modulating the Gut-Kidney Axis and Regulating Macrophage Polarization.Applied biochemistry and biotechnology · 2026Article
- Icariin-loaded liposomal nanoparticles alleviate streptozotocin-induced diabetic hepatopathy associated with modulation of ferroptosis-related and inflammatory signaling.BMC pharmacology & toxicology · 2026Article
- Nine-Week Co-Supplementation with Sugarcane Wax Alcohol (Policosanol), Phosphatidylserine, andInternational journal of molecular sciences · 2026Article
- Limbic-Predominant Cortical Magnetic Susceptibility Alterations Are Associated With Glycemic Dysregulation and Cognitive Performance in Type 2 Diabetes.CNS neuroscience & therapeutics · 2026Article
426 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent hyperglycemic state in type 2 diabetes mellitus leads to the initiation and progression of non-enzymatic glycation reaction with proteins and lipids and nucleic acids. Glycation reaction leads to the generation of a heterogeneous group of chemical moieties known as advanced glycated end products (AGEs), which play a central role in the pathophysiology of diabetic complications. The engagement of AGEs with its chief cellular receptor, RAGE, activates a myriad of signaling pathways such as MAPK/ERK, TGF-β, JNK, and NF-κB, leading to enhanced oxidative stress and inflammation. The downstream consequences of the AGEs/RAGE axis involve compromised insulin signaling, perturbation of metabolic homeostasis, RAGE-induced pancreatic beta cell toxicity, and epigenetic modifications. The AGEs/RAGE signaling instigated modulation of gene transcription is profoundly associated with the progression of type 2 diabetes mellitus and pathogenesis of diabetic complications. In this review, we will summarize the exogenous and endogenous sources of AGEs, their role in metabolic dysfunction, and current understandings of AGEs/RAGE signaling cascade. The focus of this review is to recapitulate the role of the AGEs/RAGE axis in the pathogenesis of type 2 diabetes mellitus and its associated complications. Furthermore, we present an overview of future perspectives to offer new therapeutic interventions to intervene with the AGEs/RAGE signaling pathway and to slow down the progression of diabetes-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.